Perimeter Medical Imaging Ai Inc Stock Price, News & Analysis

Perimeter Medical Imaging AI reported its Q2 2021 financial results, highlighting a net loss of $3.24 million, a decrease from $4.66 million in Q2 2020. Operating expenses increased to $3.06 million from $2 million in the previous year. Key developments included the U.S. FDA granting Breakthrough Device Designation for its imaging systems, the achievement of a 0.94 AUC in its ImgAssist AI algorithm, and plans for a pivotal study aimed at reducing breast cancer re-operation rates.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced significant progress in expanding its commercial organization, led by Chief Commercial Officer Steve Sapot. The company has hired four experienced market development managers to promote its S-Series OCT medical imaging technology in the U.S. market. Perimeter's innovative imaging system, cleared by the U.S. FDA, aims to enhance cancer surgery outcomes and reduce healthcare costs. Additionally, the company is advancing its ImgAssist AI technology under the ATLAS AI project, supported by a US$7.4 million grant.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) has announced that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC) in the U.S. This DTC eligibility aims to increase liquidity and enhance the company's presence in U.S. capital markets. CEO Jeremy Sobotta highlighted the benefits for existing shareholders, including faster execution speeds and greater opportunities to attract new investors. The company's imaging technology, including S-Series and B-Series OCT systems, is designed to improve cancer surgery outcomes.

Perimeter Medical Imaging AI (OTC:PYNKF), a leader in medical imaging technology, will participate in the 6th Annual Needham Virtual Med Tech & Diagnostics Conference on August 16-17, 2021. CEO Jeremy Sobotta will hold one-on-one virtual meetings during the event. Perimeter's FDA-cleared S-Series Optical Coherence Tomography (OCT) offers real-time visualization of excised tissue, potentially enhancing surgical outcomes. The company is also developing the B-Series OCT with ImgAssist AI, backed by a $7.4 million CPRIT grant, aimed at improving breast conservation surgery outcomes.

Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF) has appointed Dr. Sarah Butler as Vice President of Clinical and Medical Affairs, effective immediately. CEO Jeremy Sobotta expressed enthusiasm over Butler's expertise in medical affairs, expecting her to enhance clinical strategies as the company prepares for a pivotal study of its ImgAssist AI software. Dr. Butler brings extensive experience from previous roles, including her tenure at IBM Watson Health. The company focuses on transforming cancer surgery with advanced imaging tools, addressing unmet medical needs.

Perimeter Medical Imaging AI (TSX-V: PINK, OTC: PYNKF) announced CEO Jeremy Sobotta will participate in the virtual Lytham Partners Summer 2021 Investor Conference panel on breast cancer innovations on June 15, 2021, at 5:00 PM ET. The event runs from June 14-16, 2021, with one-on-one meetings available. Perimeter's FDA-cleared S-Series Optical Coherence Tomography (OCT) enhances real-time visualization during surgery, aiming for improved patient outcomes. The B-Series OCT, supported by a $7.4 million CPRIT grant, is set for a pivotal study to evaluate its impact on breast cancer surgery.

Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF) has successfully completed the technology transfer for manufacturing its S-Series Optical Coherence Tomography (OCT) imaging systems with Minnetronix Medical. This milestone allows Perimeter to scale up production efficiently and meet customer demands. The Perimeter S-Series OCT, cleared by the U.S. FDA, provides real-time margin visualization in surgical settings, potentially improving patient outcomes. The company is also advancing its ImgAssist AI technology, supported by a $7.4 million grant, and plans a pivotal study to evaluate its effectiveness in breast conservation surgery.

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) reported 2020 financial results and significant milestones. Key achievements included FDA 510(k) clearance for the S-Series OCT, paving the way for U.S. market entry. The company received a $7.4 million grant from CPRIT for its ATLAS AI project and appointed new leadership to strengthen its board. Notable future initiatives include a multi-site clinical study to assess re-operation rates in breast conservation surgery. The recent Breakthrough Device Designation from the FDA underscores the potential of its innovative technologies in enhancing surgical outcomes.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced that CEO Jeremy Sobotta will present a company overview at the 2021 Bloom Burton & Co. Healthcare Investor Conference on April 21, 2021, at 4:00 p.m. ET. The company focuses on transforming cancer surgery with advanced imaging tools. Its Optical Coherence Tomography (OCT) Imaging System offers real-time visualization of tissue margins, enhancing surgical outcomes. Perimeter is advancing the ImgAssist AI technology with a $7.4 million grant, aiming to improve breast cancer surgery results.